STOCK TITAN
  1. Home
  2. News
  3. ABBV

Abbvie Inc - ABBV STOCK NEWS

Welcome to our dedicated news page for Abbvie (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbvie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbvie's position in the market.

News
AbbVie Reports First-Quarter 2024 Financial Results
Rhea-AI Summary
AbbVie reported strong financial results for the first quarter of 2024, with diluted EPS of $0.77 on a GAAP basis and $2.31 on an adjusted basis. The company delivered net revenues of $12.310 billion, showing increases in various portfolios. AbbVie successfully completed the acquisition of ImmunoGen, expanding its oncology pipeline. The company raised its 2024 adjusted diluted EPS guidance range to $11.13 - $11.33.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Rhea-AI Summary
AbbVie announced positive topline results from a Phase 3b/4 study, LEVEL UP, comparing RINVOQ (upadacitinib) to DUPIXENT (dupilumab) in atopic dermatitis patients. Upadacitinib demonstrated superiority in achieving significant skin clearance and itch reduction. The study showed higher efficacy in primary and secondary endpoints, with a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
News
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, is inviting consumers to participate in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē. The open casting call aims to feature authentic patient stories and increase diversity within the aesthetics industry. Consumers can apply until June 4, 2024, by submitting their application on www.alle.com/castingcall.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
News
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Rhea-AI Summary
AbbVie announced positive results from the Phase 3 SELECT-GCA study of Upadacitinib (RINVOQ®) in patients with Giant Cell Arteritis. The study showed that 46% of patients treated with Upadacitinib achieved sustained remission compared to 29% on placebo. The safety profile was consistent with approved indications, with no new safety signals identified. Key secondary endpoints were also met, showing promising results for potential new treatment options in immune-mediated diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
clinical trial
-
News
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Rhea-AI Summary
AbbVie announces positive interim analysis of atogepant for migraine prevention, showcasing long-term safety and efficacy in ongoing study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
none
-
News
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, introduces two new SkinMedica acne products to address skin blemishes, providing effective skincare solutions. The SkinMedica Acne Clarifying Treatment and Pore Purifying Gel Cleanser are clinically proven to offer balanced care for acne-prone skin, focusing on efficacy and skin barrier protection. These products can be combined with the SkinMedica Pore Purifying Pro-Infusion Serum for a complete skincare protocol.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
News
AbbVie to Host First-Quarter 2024 Earnings Conference Call
Rhea-AI Summary
AbbVie (ABBV) to release first-quarter 2024 financial results on April 26, 2024, with a live webcast of the earnings conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
conferences earnings
-
News
Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®
Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, introduces CoolMonth celebration with $200 off CoolSculpting® treatment. CoolSculpting® Elite offers FDA-cleared non-invasive fat reduction. Promotions aim to support consumers seeking body contouring treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
none
-
News
NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13
Rhea-AI Summary
NIMML Institute founders and scientific director recognized for their leadership in the discovery and development of NX-13, leading to the acquisition of Landos Biopharma by AbbVie. The acquisition validates the value of NIMML's TITAN-X Precision Medicine platform in discovering immunoregulatory therapeutics for autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
acquisition
News
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
Rhea-AI Summary
Allergan Aesthetics, under AbbVie, collaborates with global medical aesthetics experts to elevate discussions on ethics in aesthetics. The 'Moving the Needle on Ethics' program aims to raise awareness, ensure transparency, and prioritize patient safety in the growing industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
Stock ABBV logo
Abbvie Inc

NYSE:ABBV

ABBV Rankings

#30 Ranked by Market Cap
#2312 Ranked by Stock Gains
#886 Ranked by Dividends

ABBV Stock Data

287.80B
1.76B
0.11%
71.92%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
North Chicago

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.